Clinical Trial Update: A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This document notes an ongoing Phase 1 clinical trial evaluating JNJ-87562761 in participants with relapsed or refractory multiple myeloma. The study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JNJ-87562761

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING